Fundraising Fox
🦊/Companies
Sign in

Vtvtherapeutics

NASDAQ: VTVT

High Point, US · Delaware corporation · 60 employees on LinkedIn · 2 known investors

Find your way into Vtvtherapeutics

518 people in our graph share verified history with the Vtvtherapeutics team — schools, employers, funds. One of them is your warm intro.

Catherine Pearce, DHSc, MBAunlockedknows Paul Sekhri · together at Teva Pharmaceuticals (overlapped)
knows the team · via Deep Genomics
×3knows the team · via Mpmcapital
×3knows the team · via TPG Global
×4knows the team · via Wake Forest University

vTv Therapeutics is a biopharmaceutical company developing oral, small molecule drugs for diabetes and other chronic diseases. Its lead candidate, cadisegliatin, is a glucokinase activator in Phase 3 trials for treating type 1 diabetes.

BiotechDigital HealthMedical Devices

Founders & leadership

RHRudy Howard
Rudy HowardinChief Financial Officer2015–2021Rudy Howard is Executive Officer of vTv Therapeutics, a biopharmaceutical company developing oral small molecule drugs for chronic diseases. He brings extensive experience in corporate leadership, mergers and acquisitions, securities law, capital markets transactions, and investor relations.
SHStephen Holcombe
Stephen HolcombeinSenior Advisor2021–2022Stephen Holcombe is an executive officer with over 20 years of experience in biopharmaceutical company leadership, including roles overseeing drug discovery operations, clinical development, manufacturing, and capital raising across multiple private and public companies, and has led two successful IPOs.
LA
Larry AltstielExecutive
JK
Jeffrey KindlerExecutive
PSPaul Sekhri
Paul Sekhriin𝕏Chair, President and CEO, vTv Therapeutics, Inc.Paul Sekhri is Chairman, President, and Chief Executive Officer of vTv Therapeutics. He brings nearly four decades of executive experience in the life sciences sector, including prior leadership roles at Novartis, ARIAD Pharmaceuticals, TPG Biotech, Teva, Sanofi, and other biopharmaceutical firms, and has served on more than 40 public and private company boards across North America and Europe.
MTMichael Tung
Michael TunginChief Financial OfficerMichael Tung is Chief Financial Officer at vTv Therapeutics, a biopharmaceutical company developing oral small-molecule drugs for diabetes and chronic diseases. He has held CFO and finance roles at public biopharmaceutical companies including Aclaris Therapeutics, FibroGen Inc., and private-stage AdvanCell, and has structured equity, debt, and royalty transactions for biotech firms.
PM
Paul MeisterNamed on SEC filing
PS
Paul SavasNamed on SEC filing
NS
Noel SpiegelNamed on SEC filing
HW
Howard WeinerNamed on SEC filing
JF
John FryNamed on SEC filing
SC
Steven CohenNamed on SEC filing

Investors · 2

JDRF T1D FundBoston
Samsara BioCapitalPalo Alto

Reported raises · per SEC filings

Form D private placements

$70.5M disclosed across 6 of 7 rounds · 2017–2024

▶$51MraisedMar 2024 · 4 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Keith HarrisDirector
  • Steven TuchExecutive Officer
  • Srinivas AkkarajuDirector
  • Raymond CheongDirector
  • Richard NelsonExecutive Officer, Director
  • Paul J. SekhriExecutive Officer, Director
  • John A. FryDirector
  • Fahed Al MarzooqiDirector
  • Howard L. WeinerDirector
Offering amount
$51M
Amount sold
$51M
First sale
Feb 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedJan 2020 · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Rudy HowardExecutive Officer
  • Noel SpiegelDirector
  • Paul SavasDirector
  • John FryDirector
  • Stephen HolcombeExecutive Officer
  • Howard WeinerDirector
  • Jeffrey KindlerDirector
  • Hersh KozlovDirector
Offering amount
$10M
Amount sold
$2M
First sale
Jan 2020
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedOct 2019 · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Howard WeinerDirector
  • Paul SavasDirector
  • John FryDirector
  • Hersh KozlovDirector
  • Jeffrey KindlerExecutive Officer, Director
  • Rudy HowardExecutive Officer
  • Stephen HolcombeExecutive Officer
  • Noel SpiegelDirector
Offering amount
$10M
Amount sold
$2M
First sale
Sep 2019
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4MraisedJul 2019 · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeffrey KindlerExecutive Officer, Director
  • Steven CohenDirector
  • John FryDirector
  • Paul SavasDirector
  • Howard WeinerDirector
  • Noel SpiegelDirector
  • Rudy HowardExecutive Officer
  • Stephen HolcombeExecutive Officer
Offering amount
$9M
Amount sold
$4M
First sale
Jun 2019
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.5MraisedJan 2019 · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Rudy HowardExecutive Officer
  • Howard WeinerDirector
  • Paul SavasDirector
  • Noel SpiegelDirector
  • Steven CohenDirector
  • Stephen HolcombeExecutive Officer
  • John FryDirector
  • Craig ParkerDirector
  • Jeffrey KindlerExecutive Officer, Director
Offering amount
$10M
Amount sold
$1.5M
First sale
Dec 2018
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10MofferedAug 2018 · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Craig ParkerDirector
  • Howard WeinerDirector
  • Paul MeisterDirector
  • Stephen HolcombeExecutive Officer
  • Noel SpiegelDirector
  • Paul SavasDirector
  • Rudy HowardExecutive Officer
  • Steven CohenDirector
  • Jeffrey KindlerExecutive Officer, Director
  • John FryDirector
Offering amount
$10M
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10MraisedDec 2017 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Rudy HowardExecutive Officer
  • Paul MeisterDirector
  • Stephen HolcombeExecutive Officer
  • Paul SavasDirector
  • Noel SpiegelDirector
  • Howard WeinerDirector
  • John FryDirector
  • Larry AltstielExecutive Officer
  • Steven CohenDirector
  • Craig ParkerDirector
  • Jeffrey KindlerExecutive Officer, Director
Offering amount
$10M
Amount sold
$10M
First sale
Dec 2017
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$117.2Mvaluation at IPOJul 2015 · $15.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Competitors · 6

by search overlap
Robinhood9 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
TradingView9 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Public8 shared keywordsPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
Seeking Alpha8 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
StockTwits8 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
TipRanks7 shared keywordsFinancial analysis and stock research platform.

Companies competing with Vtvtherapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Vtvtherapeutics do?
vTv Therapeutics is a biopharmaceutical company developing oral, small molecule drugs for diabetes and other chronic diseases. Its lead candidate, cadisegliatin, is a glucokinase activator in Phase 3 trials for treating type 1 diabetes.
Who are Vtvtherapeutics's investors?
Vtvtherapeutics's investors include JDRF T1D Fund, Samsara BioCapital.
How much funding has Vtvtherapeutics raised?
Vtvtherapeutics has disclosed $70.5M raised across 6 of its 7 known rounds.
Where is Vtvtherapeutics headquartered?
Vtvtherapeutics is headquartered in High Point, US.